TransCode retains Tungsten Advisors for strategic review of oncology portfolio
The company will explore licensing, partnership and other deals for lead candidate TTX-MC138 and its broader pipeline.
SEC filing
3 stories
The company will explore licensing, partnership and other deals for lead candidate TTX-MC138 and its broader pipeline.
SEC filing
TransCode made a prepayment to Yorkville to waive triggered amortization events after its stock traded below $1.72 for 10 of 14 trading days in September.
SEC filing
The company said 71.4% of efficacy-evaluable patients achieved stable disease, with some patients progression-free at one year and no dose-limiting toxicities reported.
SEC filing